Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
34,558
datasets available to search
ShareScore release 0.9.0
Dataset results
34,558 results for “therapy”
An anti-influenza combined therapy assessed by single cell RNA-sequencing
<p>Figures source data for<strong> </strong>"<strong>An anti-influenza combined therapy assessed by single cell RNA-sequencing</strong>"</p> <p> </p>
Network Theme: Continuous blood processing for patient specific therapies - Dr Robert Barker (University of Kent)
<p>This video is the third talk from our Future Blood Testing Network Plus Launch that took place on the 23/11/2021.</p> <p>Network Theme: Continuous blood processing for patient specific therapies - Dr Robert Barker (University of Kent)</p> <p>Bio: Dr Robert Barker is an Associate Professor in Chemistry in the School of Physical Sciences, School Director of Public Engagement, project lead for the ‘Future Human’ Signature Research, University of Kent (UoK). He is a Royal Society Industrial Fellow and the PI of the trans-disciplinary EPSRC project Optimising Me Manufacturing Systems [EP/R022534/1], exploring continuous blood processing for healthcare and developing a healthcare micro-factory that provides on-the-body manufacturing of therapeutics, continuously and in response to the body’s needs. His work focuses on the whole blood processing and the development of a manufacturing system for T-cell immunotherapies which present a cure for some of the most aggressive forms of cancer (acute lymphoblastic leukaemia and chronic lymphoblastic leukaemia). His research is at the interface of industry and the NHS to meet their needs for continuous blood monitoring and to help the shift away from the current one-size-fits-all approach to deliver patient-specific therapies.</p> <p>Further details on this event can be found at: https://futurebloodtesting.org/event/23-11-21-future-blood-testing-network-launch/</p> <p>This video is an output from the Future Blood Testing Network which is funded by EPSRC under Grant Number EP/W000652/1</p> <p>YouTube Link: https://youtu.be/T4UVEOM1cZU</p>
PortPy: Planning and Optimization for Radiation Therapy
<p>PortPy (<strong>P</strong>lanning and <strong>O</strong>ptimization for <strong>R</strong>adiation <strong>T</strong>herapy) is a community effort to develop an open source python library to facilitate the development and clinical translation of radiotherapy cancer treatment planning algorithms. PortPy includes:</p> <p>1. Research-ready data and code to promote <em>benchmarking</em>, <em>transparency</em>, <em>reproducibility </em>and <em>community</em>-<em>driven </em>development</p> <p>2. Interface to an open-source optimization package <a href="https://www.cvxpy.org/">CVXPy</a> for easy/quick prototyping and out-of-the-box access to commercial/open-source optimization engines (e.g., Mosek, Gorubi, CPLEX, IPOPT)</p> <p>3. Visualization modules to visualize relevant plan information (e.g, dose volume histograms, dose distribution, fluence map)</p> <p>4. Evaluation modules to quantify plan quality with respect to established clinical metrics (e.g., RTOG metrics, dose conformality, tumor control probability, normal tissue control probability)</p> <p>Data needed for optimization and algorithm development (e.g., a set of beams/beamlets/voxels, dose contribution of each beamlet to each voxel) are provided for a set of pre-specified machine parameters (e.g., beam/colimator/couch angles). We initially provide these data for a set of publicly available dataset from TCIA. We hope to expand our dataset in the future. The data needed for optimization is extracted from the research version of Eclipse<sup>TM</sup> treatment planning system (<a href="https://www.varian.com/">Varian Medical Systems</a>) using its API.</p>
Replication package for: What Good are Treatment Effects Without Treatment? Mental Health and the Reluctance to Use Talk Therapy
<p>Includes the replication package for the paper titled, "What Good are Treatment Effects Without Treatment? Mental Health and the Reluctance to Use Talk Therapy," accepted for publication by the Review of Economic Studies, December 31, 2023.</p>
Therapeutic working alliance in brief therapy with college students: In-person versus telemental health
<p>This study compared the therapeutic working alliance in brief counseling using two delivery methods: synchronous video delivery and in-person delivery. The alliance was measured using the Working Alliance Inventory (client version). Participants were 49 undergraduate college students between the ages of 18 and 22. Solution-Focused Brief Therapy was the treatment protocol, and the study used a randomized, controlled design. Welch's t-tests and non-inferiority analyses were conducted, in addition to hierarchical regression analyses to examine the predictive value of the working alliance on post-treatment anxiety. Non-inferiority statistical analyses indicated that there was no statistically significant difference in working alliance for online delivery compared to in-person. A hierarchical regression anaIysis suggests that the therapeutic working alliance contributed to anxiety treatment outcomes for college student participants.</p>
Data for: High-throughput micro-CT analysis identifies sex-dependent biomarkers of erosive arthritis in TNF-Tg mice and differential response to anti-TNF therapy
Open the record for dataset details and reuse information.
The impact of cognitive remediation therapy on lower eye movement and word fluency function: A prospect for improvement of eye movement and cognitive function in schizophrenia
Open the record for dataset details and reuse information.
Kufor-Rakeb Syndrome-Associated Psychosis: A Novel Loss-of-Function ATP13A2 Variant and Response to Antipsychotic Therapy
Open the record for dataset details and reuse information.
Data from: Clinical outcomes and safety of polymyxin B versus tigecycline combination therapy for pneumonia of carbapenem-resistant Klebsiella pneumoniae: A retrospective cohort study
<p><strong>Purpose:</strong> Infection by carbapenem-resistant <em>Klebsiella pneumoniae</em> (CRKP) has high mortality. There is no clear optimal therapeutic choice for pneumonia caused by CRKP. The aim of this study was to compare the clinical outcomes and safety of the standard doses of polymyxin B-based regimens vs tigecycline-based regimens and to identify risk factors for mortality.</p> <p><strong>Methods:</strong><strong> </strong>This retrospective cohort study included patients with pneumonia caused by CRKP for three years. The primary outcomes were 7-day bacterial eradication rate and 14- and 28-day all-cause mortality. The secondary outcome was incidence of acute kidney injury.</p> <p><strong>Results:</strong><strong> </strong>Seventy-three patients were included in this study, 29 in the<strong> </strong>polymyxin B-based combination therapy group and 44 in tigecycline-based combination therapy group. There were no significant differences between the two groups in terms of the 7-day bacterial eradication rate (31.0% vs 20.5%, <em>P</em>=0.409), the 14-day all-cause mortality (37.9% vs 22.7%, <em>P</em>=0.160), and the incidence of acute kidney injury (14.3% vs 6.8%, <em>P</em>=0.526). The 28-day all-cause mortality in the polymyxin B-based therapy group was higher than in the tigecycline-based group (75.9% vs 45.5%, <em>P</em>=0.010). Binary logistic regression analysis revealed that male and previous use of carbapenems were independent factors associated with 28-day all-cause mortality for patients treated with polymyxin B (<em>P</em><0.05).</p> <p><strong>Conclusions:</strong><strong> </strong>Polymyxin B-based combination therapy at the standard dose should be used with caution for patients with CRKP-induced pneumonia, especially for men who used carbapenems prior to CRKP detection.</p>
Fig. 2. A in Microstructural Impact of Ischemia and Bone Marrow-Derived Cell Therapy Revealed With Diffusion Tensor Magnetic Resonance Imaging Tractography of the Heart In Vivo
Fig. 2. A picture of four male - female pairs of Amblyomma variegatum attached on a cow examined during this survey. © Anne Laudisoit.
Fig. 1 in Microstructural Impact of Ischemia and Bone Marrow-Derived Cell Therapy Revealed With Diffusion Tensor Magnetic Resonance Imaging Tractography of the Heart In Vivo
Fig. 1. Map of Kisangani and Major transhumance routes from probable departure location to Kisangani city, DR Congo.
Dual Drug Delivery in Cancer Therapy Using Graphene Oxide-Based Nanoplatforms
Open the record for dataset details and reuse information.
Inflammatory bowel disease and immune-mediated inflammatory diseases (IMID) therapy
<p>Immune-mediated inflammatory diseases (IMID) and inflammatory bowel diseases share therapeutic targets and approval drugs. This table tries to summarize shared therapeutic approval drugs</p> <p>Additional information can be found at www.ibd-eii.com</p>
Inflammatory bowel disease and extra intestinal manifestations therapy
<p>Inflammatory bowel disease often present with associated extra intestinal manifestations, here you can find proved therapies that are known to have an impact on extra intestinal manifestation course.</p> <p>Additional information can be found at www.ibd-eii.com</p>
Source data sets_Figure 1, 2, 6_Salmonella cancer therapy metabolically disrupts tumours at the collateral cost of T cell immunity
<p>Flow cytometry data files associated with Copland <em>et al., </em><strong><em><span>Salmonella </span></em></strong><strong><span>cancer therapy metabolically disrupts tumours at the collateral cost of T cell immunity.</span></strong></p> <p><span>Data associated to Figures 1, 2 and 6. <br></span></p>
Studying Therapy Effects and Disease Outcomes in Silico using Artificial Counterfactual Tissue Samples
<p>Counterfactual samples created by our generative method the CF-HistoGAN introduced in https://doi.org/10.48550/arXiv.2302.03120. This model was trained on and transformed data from 2 different datasets: the colorectal cancer (CRC) dataset by Schürch et al. https://doi.org/10.1016/j.cell. 2020.07.005 and the cutaneous T cell lymphoma (CTCL) by (Phillips et al https://doi.org/10.1038/s41467-021-26974-6.</p>
Nanocomposite formulation for a sustained release of free drug and drug-loaded responsive nanoparticles: an approach for a local therapy of glioblastoma multiforme
<p>Malignant gliomas are a type of primary brain tumour that originates in glial cells. Among them, glioblastoma multiforme (GBM) is the most common and the most aggressive brain tumour in adults, classified as grade IV by the World Health Organization. The standard care for GBM, known as the Stupp protocol includes surgical resection followed by oral chemotherapy with temozolomide (TMZ). This treatment option provides a median survival prognosis of only 16–18 months to patients mainly due to tumour recurrence. Therefore, enhanced treatment options are urgently needed for this disease. Here we show the development, characterization, and in vitro and in vivo evaluation of a new composite material for local therapy of GBM post-surgery. We developed responsive nanoparticles that were loaded with paclitaxel (PTX), and that showed penetration in 3D spheroids and cell internalization. These nanoparticles were found to be cytotoxic in 2D (U-87 cells) and 3D (U-87 spheroids) models of GBM. The incorporation of these nanoparticles into a hydrogel facilitates their sustained release in time. Moreover, the formulation of this hydrogel containing PTX-loaded responsive nanoparticles and free TMZ was able to delay tumour recurrence in vivo after resection surgery. Therefore, our formulation represents a promising approach to develop combined local therapies against GBM using injectable hydrogels containing nanoparticles.</p>
Supporting Material: Proof-of-principle of 3D-printed track-end detectors for dosimetry in proton therapy
<p><strong>Project description and contents of the submitted manuscript:</strong></p> <p><strong>Background: </strong>Dosimetric equipment in particle therapy (PT) is associated with high costs. There is a lack of versatile, tissue-equivalent detectors suitable for in-vivo dosimetry. Faraday-cup (FC) type detectors are sensitive to stopped protons, i.e. to trackends. They experience a renaissance in PT as they can cope with high dose rates. Owing to their simple functional principle, production of FC could benefit from the dynamic technological developments in additive manufacturing of sensors.</p> <p><strong>Purpose: </strong>To build FC-type detectors for PT by standard 3D-printing. This study seeks to build an integrating, single-channel FC for replacement of a traditional FC and a 2×2 array of FC elements indicating the feasibility of a spatially resolving detector.</p> <p><strong>Methods: </strong>Samples of FCs were produced with a dual-extruder 3D-printer with polylactic-acid filaments, which contained graphite in the conductive parts of the detector. Production was optimizied in terms of materials and printing temperature. Samples were characterized by electrical tests and non-destructive 3D x-ray imaging. Beam tests were conducted at a clinical PT machine.</p> <p><strong>Results: </strong>Operational FC-type detectors for proton fields were printed. The detected charge of the single-channel FC corresponded qualitatively to the one of a traditional FC. A 2 × 2 FC array was fabricated in a single run. There was a linear relationship between the response of the individual FC elements and the machine output.</p> <p><strong>Conclusions: </strong>3D-printing is a viable method for producing low-cost, tissue-equivalent, FC-type detectors for PT. They could potentially be used as track-end detectors in anthropomorphic phantoms.</p> <h3>Shared files:</h3> <p>2x2_FC_matrix: design CAD files of FC array</p> <p>Single_channel_FC: design CAD files of simplified, single-channel FC</p> <p>CT_matrix: high-resolution x-ray CT image set of the 2x2 FC array</p> <p>Measured_values_for_MedPhys_technical_note: Excel sheet of the data presented in the paper</p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p> <p> </p>
Figures for the publication ''The role of small extracellular vesicles and microRNA as their cargo in the spinal cord injury pathophysiology and therapy''
Open the record for dataset details and reuse information.
Metabolomic Analysis of the Effects of Leptin Replacement Therapy in Patients with Lipodystrophy
<p>Context and Objective </p><p>Leptin treatment has dramatic clinical effects on glucose and lipid metabolism in leptin-deficient patients with lipodystrophy. Further elucidation of metabolic effects of exogenous leptin therapy will shed light on understanding leptin physiology in humans. Our objective was to utilize metabolomic profiling to examine the changes associated with administration of short-term metreleptin therapy in patients with lipodystrophy.</p> Study Design <p>We conducted a pre-post treatment study in 19 patients (75% female) with varying forms of lipodystrophy (congenital generalized lipodystrophy, n=10; acquired generalized lipodystrophy, n=1; familial partial lipodystrophy, n=8) who received daily subcutaneous metreleptin injections for a period of 16 - 23 weeks. A 3-hour oral glucose tolerance test and body composition measurements were conducted before and after the treatment period, and fasting blood samples were used for metabolomic profiling. The study outcome aimed at measuring changes in physiologically relevant metabolites pre- and post- leptin therapy.</p> Results <p>Metabolomic analysis revealed changes in pathways involving branched-chain amino acid metabolism, fatty acid oxidation, protein degradation, urea cycle, tryptophan metabolism, nucleotide catabolism, vitamin E, and steroid metabolism. Fold-changes in pre- to post-treatment metabolite levels indicated increased breakdown of fatty acids, branched chain amino acids proteins, and nucleic acids.</p> Conclusions <p>Leptin replacement therapy has significant effects on important metabolic pathways implicated in patients with lipodystrophy. Continued metabolomic studies may provide further insight into the mechanisms of action of leptin replacement therapy and provide novel biomarkers of lipodystrophy.</p> <p></p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.